secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeOne Medicines Ltd. (ONC)
CIK:        0001651308
Form:       8-K
Filed at:   2026-08-05T10:02:36+00:00
Accession:  0001628280-26-052877
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BeOne Medicines Q2 revenue up 30% to $1.7B; raises FY2026 guidance
------------------------------------------------------------------

- Q2 total revenue $1.71B (+30% YoY); BRUKINSA revenue $1.2B (+31% YoY).
- GAAP diluted EPS $2.05; non-GAAP diluted EPS $3.84 (up 71% YoY).
- Raised FY2026 revenue guidance to $6.6-6.8B; GAAP op income $1.0-1.1B.
- Q2 free cash flow $435M (+98% YoY); six-month total revenue $3.22B (+32% YoY).
- CEO cites strong hematology franchise and pipeline momentum.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651308/000162828026052877/0001628280-26-052877-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651308/000162828026052877/bgne-20260805.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-052877

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer